Literature DB >> 6296233

Identification of normal and transformed lymphocyte subsets of nonhuman primates with monoclonal antibodies to human lymphocytes.

R H Neubauer, C J Briggs, K B Noer, H Rabin.   

Abstract

Monoclonal antibodies (MAb) that detect specific lymphocyte subsets of man were tested for their reactivity with peripheral blood lymphocytes (PBL) and established cell lines of owl monkeys (Aotus trivirgatus) and marmosets (Saguinus spp). Results of these studies showed that certain determinants were conserved and that the pattern of reactivity observed in one genus (or even species) could not be used to predict the reactivity in another. On owl monkey PBL, reactivity equivalent to that on human PBL was observed with OKT11a, anti-Leu 3a, B1, and anti-HLA-DR MAb thus detecting T cell, helper/inducer T cell, B cell, and HLA-DR determinants. After neuraminidase treatment of owl monkey PBL, reactivity with anti-Leu 5 and OKT8 (T cell and suppressor/cytotoxic T cell determinants) was observed. Cell separation experiments indicated these determinants were found on lymphocytes with the same general properties as those of human origin. The use of these MAb to examine owl monkeys infected with Herpesvirus saimiri and tumor cell lines established from H. saimiri-inoculated monkeys revealed that the virus was found in OKT11a-positive, B1-negative cells. In chronically infected nondiseased animals, H. saimiri was found in anti-HLA-DR-negative cells and was restricted to anti-Leu 3a-positive cells (two animals) or was nearly equally distributed in anti-Leu 3a-positive and negative cells (one animal). Established H. saimiri tumor cell lines had the phenotype OKT11 a-positive, anti-HLA-DR-positive, B1-negative and were either anti-Leu 3a-positive or negative. Studies of interleukin 2-responsive tumor cells in short-term culture suggested the tumor was composed of virus-positive anti-Leu 3a-positive and negative populations.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6296233

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Deletion mutants of herpesvirus saimiri define an open reading frame necessary for transformation.

Authors:  S C Murthy; J J Trimble; R C Desrosiers
Journal:  J Virol       Date:  1989-08       Impact factor: 5.103

2.  Nononcogenic deletion mutants of herpesvirus saimiri are defective for in vitro immortalization.

Authors:  R C Desrosiers; D P Silva; L M Waldron; N L Letvin
Journal:  J Virol       Date:  1986-02       Impact factor: 5.103

3.  Herpesvirus saimiri strains from three DNA subgroups have different oncogenic potentials in New Zealand white rabbits.

Authors:  M M Medveczky; E Szomolanyi; R Hesselton; D DeGrand; P Geck; P G Medveczky
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

4.  Comparison of peripheral blood leukocyte kinetics after live Escherichia coli, endotoxin, or interleukin-1 alpha administration. Studies using a novel interleukin-1 receptor antagonist.

Authors:  A S Hawes; E Fischer; M A Marano; K J Van Zee; C S Rock; S F Lowry; S E Calvano; L L Moldawer
Journal:  Ann Surg       Date:  1993-07       Impact factor: 12.969

5.  Transformation of owl monkey T cells in vitro with Herpesvirus saimiri.

Authors:  H Rabin; R F Hopkins; R C Desrosiers; J R Ortaldo; J Y Djeu; R H Neubauer
Journal:  Proc Natl Acad Sci U S A       Date:  1984-07       Impact factor: 11.205

6.  Characterization of a human blood monocyte subset with low peroxidase activity.

Authors:  Y Akiyama; P J Miller; G B Thurman; R H Neubauer; C Oliver; T Favilla; J A Beman; R K Oldham; H C Stevenson
Journal:  J Clin Invest       Date:  1983-09       Impact factor: 14.808

7.  Expression of the collagen-like putative oncoprotein of Herpesvirus saimiri in transformed T cells.

Authors:  M M Medveczky; P Geck; R Vassallo; P G Medveczky
Journal:  Virus Genes       Date:  1993-12       Impact factor: 2.332

8.  Characterization of circulating natural killer cells in neotropical primates.

Authors:  Angela Carville; Tristan I Evans; R Keith Reeves
Journal:  PLoS One       Date:  2013-11-11       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.